However, IFITM1 was significantly downregulated in some malignancies, such as kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), and prostate adenocarcinoma (PRAD). Here, IFITM1 is linked to prostate adenocarcinoma.